ID | 1187 |
Name of the vaccine | Sonnei vaccine 1790GAHB |
Microbe | Bacteria |
Disease name | Bacillary Dysentery (Shigellosis) |
Name of bacteria | Shigella genus |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 22 to 50 years |
Description of the vaccine | Shigella sonnei vaccine. |
Name of the manufacturer | GlaxoSmithKline |
Name of the manufacturing country | France |
Year of manufacture | 2017 |
Clinical Phase status | Clinical - Phase 1 |
Bacterial strain | Gram-negative bacteria. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Three doses, gap of 4 weeks and one booster dose. |
Mechanism of action | Anti-S. sonnei lipopolysaccharide (LPS) antibody. |
Route of administration | Intramuscular |
Indications | Prevents the disease caused by Shigella sonnei. |
Export | NA |
Approval | NA |
Adjuvant | Aluminium hydroxide |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT03089879 |
Reference | https://adisinsight.springer.com/drugs/800039699 |
Other name | NA |
Additional Links | NA
|